13877-76-4
Chemical Structure
Formycin B
- CAS No.: 13877-76-4
- Formula:C10H12N4O5
- Molecular Weight:268.23
IUPAC Name: 3-((2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,4-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
InChIKey: MTCJZZBQNCXKAP-KSYZLYKTSA-N
SMILES: O[C@H]1[C@@H](O)[C@H](C2=NNC3=C2NC=NC3=O)O[C@@H]1CO
Biological Activity: Formycin B is an orally active PNP and PARP inhibitor. Formycin B inhibits influenza A virus proliferation and the replication of intracellular Trypanosoma cruzi, Leishmania, and pathogenic trypanosomes by competitively inhibiting PNP (Ki = 68-100 μM) and PARP (quail Ki = 68.9-75.0 μM), and by inhibiting DNA, RNA, and protein synthesis and cell proliferation. Formycin B can be used for research on influenza, PNP deficiency, leukemia, Chagas disease, leishmaniasis, and trypanosomiasis[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Formycin B | Formycin B is an orally active PNP and PARP inhibitor. Formycin B inhibits influenza A virus proliferation and the replication of intracellular Trypanosoma cruzi, Leishmania, and pathogenic trypanosomes by competitively inhibiting PNP (Ki = 68-100 μM) and PARP (quail Ki = 68.9-75.0 μM), and by inhibiting DNA, RNA, and protein synthesis and cell proliferation. Formycin B can be used for research on influenza, PNP deficiency, leukemia, Chagas disease, leishmaniasis, and trypanosomiasis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ishizuka M, et al. Biological studies on formycin and formycin B. The Journal of Antibiotics. 1968 Jan 25;21(1):5-12.
- [2]. Cowan MJ, et al. Effects of formycin B on human lymphocyte deoxyribonucleic acid synthesis: Optimization of cell culture conditions. Biochemical Pharmacology. 1981 Oct 1;30(19):2651-6.
- [3]. Chern JW, et al. Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase. Journal of medicinal chemistry. 1993 Apr;36(8):1024-31.
- [4]. Müller WE, et al. Influence of formycin B on polyadenosine diphosphoribose synthesis in vitro and in vivo. Cancer research. 1975 Dec;35(12):3673-81.
- [5]. McCabe RE, et al. In vitro and in vivo activities of formycin B against Trypanosoma cruzi. Antimicrobial agents and chemotherapy. 1985 Apr;27(4):491-4.
- [6]. Carson DA, et al. Phosphorylation and anti-leishmanial activity of formycin B. Biochemical and Biophysical Research Communications. 1981 Jun 16;100(3):1377-83.
- [7]. Hofflin JM, et al. Difluoromethylornithine and formycin B in toxoplasmosis. Journal of Infectious Diseases. 1985 Nov 1;152(5):1101-.
- [8]. Giziewicz J, et al. Antiviral and antimetabolic activities of formycin and its N1-, N2-, 2′-O-and 3′-O-methylated derivatives. Biochemical Pharmacology. 1975 Oct 1;24(19):1813-7.
